Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents
暂无分享,去创建一个
Sunil V. Rao | M. Price | S. Pocock | M. Krucoff | M. Leon | S. Mehta | M. Morice | D. Cohen | J. Tanguay | P. Urban | B. Faurie | Thomas McAndrew | M. Abdel-Wahab | H. Stoll | C. Díaz | B. Mclaurin | Yiran Zhang | B. McLaurin | T. McAndrew | M. Abdel‐Wahab | S. Rao | D. Cohen | D. Cohen
[1] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[2] M. Price,et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk , 2019, European heart journal.
[3] M. Price,et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.
[4] A. Parkhomenko,et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation , 2019, The New England journal of medicine.
[5] D. Kandzari,et al. Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis , 2018, JAMA cardiology.
[6] Deepak L. Bhatt,et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. , 2018, Circulation.
[7] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[8] S. Pocock,et al. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. , 2017, Journal of the American College of Cardiology.
[9] J. Messenger,et al. Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). , 2016, The American journal of cardiology.
[10] M. Valgimigli,et al. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. , 2016, JACC. Cardiovascular interventions.
[11] F. Eberli,et al. Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.
[12] S. Pocock,et al. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. , 2013, American heart journal.
[13] David J Cohen,et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. , 2013, JAMA.
[14] G. Schuler,et al. Why are we still using coronary bare-metal stents? , 2013, Journal of the American College of Cardiology.
[15] Jeroen J. Bax,et al. Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.
[16] Sunil V. Rao,et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. , 2012, JACC: Cardiovascular Interventions.
[17] Douglas Weaver,et al. Third universal definition of myocardial infarction. , 2012, Circulation.
[18] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[19] Saibal Kar,et al. Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.
[20] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[21] E. Antman,et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.
[22] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[23] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[24] P. Fitzgerald,et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.
[25] Gregg W Stone,et al. One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.
[26] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[27] R B D'Agostino,et al. Age-adjusted survival curves with application in the Framingham Study. , 1995, Statistics in medicine.
[28] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.
[29] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.